Regeneron’s FDA priority review for cemdisiran and hedge fund interest highlight its AI-driven healthcare pipeline.
Regeneron Pharmaceuticals (NASDAQ:REGN) secured FDA priority review for cemdisiran, targeting generalized myasthenia gravis, with a November 2026 action date. The European Medicines Agency also accepted regulatory applications, expecting a decision in late 2027. Data from the Phase 3 NIMBLE trial supports the filings, focusing on subcutaneous dosing every 12 weeks.
RBC Capital maintained a “Sector Perform” rating and $707 price target on REGN but noted AbbVie’s acquisition of Apogee Therapeutics as a competitive threat. The deal could challenge Regeneron’s Dupixent with a next-generation IL-13 antibody program. Regeneron remains a top pick among hedge funds for AI-powered healthcare stocks.